Latest & greatest articles for hydrocortisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrocortisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrocortisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrocortisone

21. Hydrocortisone sodium phosphate (Softacor) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases

Hydrocortisone sodium phosphate (Softacor) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases | Report | National Health Care Institute You are here: Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases Search within English part of National Health (...) Care Institute Search Hydrocortisone sodium phosphate (Softacor®) for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases Zorginstituut Nederland has carried out an assessment of the medicinal product hydrocortisone sodium phosphate (Softacor®) can be included in the Medicine Reimbursement System (GVS). The Ministry requested a marginal assessment. Softacor® is an ocular corticosteroid registered for the treatment of mild non-infectious allergic or inflammatory

2018 National Health Care Institute (Zorginstituut Nederland)

22. Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery Full Text available with Trip Pro

Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery Management of adult patients with classic congenital adrenal hyperplasia (CAH) is challenging and often complicated by obesity, metabolic syndrome, and adverse cardiovascular risk. Alterations in weight can influence cortisol kinetics. A 19-year-old woman with classic CAH and morbid obesity experienced persistent elevations of androgen levels while receiving oral (...) glucocorticoid therapy. Control of adrenal androgens was improved with continuous subcutaneous hydrocortisone infusion therapy, but obesity-related comorbidities persisted. After undergoing sleeve gastrectomy, the patient experienced dramatic weight loss, with improvement in insulin sensitivity and fatty liver in the postbariatric period. Cortisol clearance studies performed to evaluate changes in hydrocortisone dose requirements showed marked alternations in cortisol pharmacokinetics with decreases

2017 Journal of the Endocrine Society

23. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. (Abstract)

Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. Dexamethasone to prevent bronchopulmonary dysplasia in very preterm neonates was associated with adverse neurodevelopmental events. Early low-dose hydrocortisone treatment has been reported to improve survival without bronchopulmonary dysplasia but its safety with regard to neurodevelopment remains to be assessed.To assess whether early hydrocortisone (...) therapy in extremely preterm infants is associated with neurodevelopmental impairment at 2 years of age.An exploratory secondary analysis of the PREMILOC (Early Low-Dose Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia in Extremely Preterm Infants) randomized clinical trial conducted between 2008 and 2014 in 21 French neonatal intensive care units. Randomization was stratified by gestational age groups. Neurodevelopmental assessments were completed from 2010 to 2016.After birth

2017 JAMA Controlled trial quality: predicted high

24. Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial Full Text available with Trip Pro

Hydrocortisone 1% cream and sertaconazole 2% cream to treat facial seborrheic dermatitis: A double-blind, randomized clinical trial Seborrheic dermatitis (SD) is a chronic dermatitis with periods of remission and relapse that requires long-term treatment.We compared the efficacy and safety of treatment with sertaconazole with standard corticosteroid medications in adults with facial SD.In this double-blind, randomized controlled trial, 60 patients with a diagnosis of SD were enrolled. Patients (...) were instructed to apply either sertaconazole 2% cream (30 patients) or hydrocortisone 1% cream (30 patients) twice daily to the affected area of the face. The severity of facial SD was assessed at 0, 2, and 4 weeks of treatment. Secondary efficacy measures included patient assessment of seborrhea, adverse events, and improvement percentage (IP).SD lesions cleared significantly (p < .05) and similarly in both treatment groups (p > .05). Both treatments resulted in significant improvement of SD

2016 International journal of women's dermatology Controlled trial quality: predicted high

25. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial. Adjunctive hydrocortisone therapy is suggested by the Surviving Sepsis Campaign in refractory septic shock only. The efficacy of hydrocortisone in patients with severe sepsis without shock remains controversial.To determine whether hydrocortisone therapy in patients with severe sepsis prevents the development of septic shock.Double-blind, randomized clinical trial conducted (...) from January 13, 2009, to August 27, 2013, with a follow-up of 180 days until February 23, 2014. The trial was performed in 34 intermediate or intensive care units of university and community hospitals in Germany, and it included 380 adult patients with severe sepsis who were not in septic shock.Patients were randomly allocated 1:1 either to receive a continuous infusion of 200 mg of hydrocortisone for 5 days followed by dose tapering until day 11 (n = 190) or to receive placebo (n = 190

2016 JAMA Controlled trial quality: predicted high

26. Perioperative Hydrocortisone Reduces Major Complications After Pancreaticoduodenectomy: A Randomized Controlled Trial (Abstract)

Perioperative Hydrocortisone Reduces Major Complications After Pancreaticoduodenectomy: A Randomized Controlled Trial The aim of this study was to study whether post-pancreaticoduodenectomy complications (PPDC) in high-risk patients can be reduced with hydrocortisone.Soft pancreas is a well-known risk factor for PPDC. Previously, we have shown that patients with >40% acini in the pancreatic transection line are most prone to PPDC. Recent studies have demonstrated that surgical trauma leads (...) to inflammation of the pancreatic remnant, which precedes PPDC.On the basis of power analysis, randomized controlled trial (RCT) (Clinicaltrials.gov NCT01460615), 155 patients (February 2011-May 2015) scheduled for pancreaticoduodenectomy were randomized to intravenous (i.v.) treatment with hydrocortisone 100 mg or placebo. All patients received the first dose at the induction of anesthesia. During the operation, the percentage of acini was calculated from pancreatic transection line frozen samples

2016 EvidenceUpdates Controlled trial quality: predicted high

27. Randomised controlled trial: Prophylactic low-dose hydrocortisone treatment increases the rate of survival without bronchopulmonary dysplasia in extremely preterm infants

Randomised controlled trial: Prophylactic low-dose hydrocortisone treatment increases the rate of survival without bronchopulmonary dysplasia in extremely preterm infants Prophylactic low-dose hydrocortisone treatment increases the rate of survival without bronchopulmonary dysplasia in extremely preterm infants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prophylactic low-dose hydrocortisone treatment increases the rate of survival

2016 Evidence-Based Medicine

28. Plenadren - hydrocortisone

Plenadren - hydrocortisone 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. 21 July2011 EMA/CHMP/424438/2011 Committee for Medicinal Products for Human Use (CHMP) Assessment report Plenadren International nonproprietary name (...) : hydrocortisone Procedure No. EMEA/H/C/2185 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/CHMP/424438/2011 Page 2/69 Table of contents 1 3 Background information on the procedure 1.1 3 Submission of the dossier 1.2 4 Steps taken for the assessment of the product 2 6 Scientific discussion 2.1 6 Introduction 2.2 7 Quality aspects 2.2.1 7 Introduction 2.2.2 7 Active Substance 2.2.3 8 Finished Medicinal Product 2.2.4 9 Discussion

2011 European Medicines Agency - EPARs

29. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. Full Text available with Trip Pro

Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. The role of stress-dose hydrocortisone in the management of trauma patients is currently unknown.To test the efficacy of hydrocortisone therapy in trauma patients.Multicenter, randomized, double-blind, placebo-controlled HYPOLYTE (Hydrocortisone Polytraumatise) study. From November 2006 to August 2009, 150 patients with severe trauma were included in 7 intensive care units in France.Patients were (...) randomly assigned to a continuous intravenous infusion of either hydrocortisone (200 mg/d for 5 days, followed by 100 mg on day 6 and 50 mg on day 7) or placebo. The treatment was stopped if patients had an appropriate adrenal response.Hospital-acquired pneumonia within 28 days. Secondary outcomes included the duration of mechanical ventilation, hyponatremia, and death.One patient withdrew consent. An intention-to-treat (ITT) analysis included the 149 patients, a modified ITT analysis included 113

2011 JAMA Controlled trial quality: predicted high

30. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review

Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

31. Hydrocortisone therapy for patients with septic shock. Full Text available with Trip Pro

Hydrocortisone therapy for patients with septic shock. Hydrocortisone is widely used in patients with septic shock even though a survival benefit has been reported only in patients who remained hypotensive after fluid and vasopressor resuscitation and whose plasma cortisol levels did not rise appropriately after the administration of corticotropin.In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 251 patients to receive 50 mg of intravenous hydrocortisone (...) and 248 patients to receive placebo every 6 hours for 5 days; the dose was then tapered during a 6-day period. At 28 days, the primary outcome was death among patients who did not have a response to a corticotropin test.Of the 499 patients in the study, 233 (46.7%) did not have a response to corticotropin (125 in the hydrocortisone group and 108 in the placebo group). At 28 days, there was no significant difference in mortality between patients in the two study groups who did not have a response

2008 NEJM Controlled trial quality: predicted high

32. Drugs - Hydrocortisone

Drugs - Hydrocortisone Hydrocortisone HYC Drugs October 2006 Page 1 of 2 Drugs PRESENTATION Ampoule containing 100 milligrams hydrocortisone as either sodium succinate or sodium phosphate in 1ml. OR Solu-cortef a powder for reconstitution with up to 2ml of water. ACTIONS Glucocorticoid drug that reduces in?ammation and suppresses immune response. CAUTIONS None relevant to a single dose. If patient is likely to require thrombolysis then intramuscular administration of any drug should be avoided (...) . INDICATIONS Severe or life threatening asthma – where call- hospital time is >30 minutes. Anaphylaxis. Addisonian Crisis. CONTRA-INDICATIONS Known allergy (which will be to the sodium succinate or sodium phosphate rather than the hydrocortisone itself). SIDE EFFECTS Sodium phosphate may cause burning or itching sensation in the groin if administered too quickly.HYC Hydrocortisone Page 2 of 2 October 2006 Drugs Drugs DOSAGE AND ADMINISTRATION Anaphylaxis or Asthma Route: IV OR IM when IV access

2007 Joint Royal Colleges Ambulance Liaison Committee

33. Hydrocortisone

Hydrocortisone Hydrocortisone HYC Drugs October 2006 Page 1 of 2 Drugs PRESENTATION Ampoule containing 100 milligrams hydrocortisone as either sodium succinate or sodium phosphate in 1ml. OR Solu-cortef a powder for reconstitution with up to 2ml of water. ACTIONS Glucocorticoid drug that reduces in?ammation and suppresses immune response. CAUTIONS None relevant to a single dose. If patient is likely to require thrombolysis then intramuscular administration of any drug should be avoided (...) . INDICATIONS Severe or life threatening asthma – where call- hospital time is >30 minutes. Anaphylaxis. Addisonian Crisis. CONTRA-INDICATIONS Known allergy (which will be to the sodium succinate or sodium phosphate rather than the hydrocortisone itself). SIDE EFFECTS Sodium phosphate may cause burning or itching sensation in the groin if administered too quickly.HYC Hydrocortisone Page 2 of 2 October 2006 Drugs Drugs DOSAGE AND ADMINISTRATION Anaphylaxis or Asthma Route: IV OR IM when IV access

2006 Joint Royal Colleges Ambulance Liaison Committee

34. Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia Full Text available with Trip Pro

Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia Hydrocortisone infusion may improve survival in patients with severe community-acquired pneumonia | Critical Care | Full Text Advertisement Menu Search Search all BMC articles Search Menu Table of Contents and John A Kellum Critical Care 2005 9 :E24 © BioMed Central Ltd 2005 Published: 20 October 2005 Citation Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, Della PR, Giorgio C (...) , Blasi F, Umberger R, Meduri GU: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242–248 [ ]. Hypothesis Hydrocortisone infusion in severe community-acquired pneumonia (CAP) attenuates systemic inflammation and leads to earlier resolution of pneumonia and a reduction in sepsis-related complications. Methods Design Prospective, randomized, double-blind, placebo-controlled multi-center clinical trial. Setting Intensive

2005 Critical Care - EBM Journal Club

35. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. (Abstract)

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Septic shock may be associated with relative adrenal insufficiency. Thus, a replacement therapy of low doses of corticosteroids has been proposed to treat septic shock.To assess whether low doses of corticosteroids improve 28-day survival in patients with septic shock and relative adrenal insufficiency.Placebo-controlled, randomized, double-blind, parallel-group trial performed (...) in 19 intensive care units in France from October 9, 1995, to February 23, 1999.Three hundred adult patients who fulfilled usual criteria for septic shock were enrolled after undergoing a short corticotropin test.Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50- micro g tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days.Twenty-eight-day survival distribution in patients with relative adrenal

2002 JAMA Controlled trial quality: predicted high

36. Hydrocortisone

Hydrocortisone Drug Approval Package: Hydrocortisone NDA #040310 FDA Application U.S. Food & Drug Administration Search FDA FDA Application - Hydrocortisone Company: Thames Pharmacal Application No.: 040310 Approval Date: 12/29/2000 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 31, 2003 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file formats, see . Language Assistance Available

2000 FDA - Drug Approval Package

37. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. (Abstract)

Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Reports of mild hypocortisolism in chronic fatigue syndrome led us to postulate that low-dose hydrocortisone therapy may be an effective treatment.In a randomised crossover trial, we screened 218 patients with chronic fatigue. 32 patients met our strict criteria for chronic fatigue syndrome without co-morbid psychiatric disorder. The eligible patients received consecutive treatment with low-dose hydrocortisone (5 (...) mg or 10 mg daily) for 1 month and placebo for 1 month; the order of treatment was randomly assigned. Analysis was by intention to treat.None of the patients dropped out. Compared with the baseline self-reported fatigue scores (mean 25.1 points), the score fell by 7.2 points for patients on hydrocortisone and by 3.3 points for those on placebo (paired difference in mean scores 4.5 points [95% CI 1.2-7.7], p=0.009). In nine (28%) of the 32 patients on hydrocortisone, fatigue scores reached

1999 Lancet Controlled trial quality: predicted high

38. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. (Abstract)

Low-dose hydrocortisone for treatment of chronic fatigue syndrome: a randomized controlled trial. Chronic fatigue syndrome (CFS) is associated with a dysregulated hypothalamic-pituitary adrenal axis and hypocortisolemia.To evaluate the efficacy and safety of low-dose oral hydrocortisone as a treatment for CFS.A randomized, placebo-controlled, double-blind therapeutic trial, conducted between 1992 and 1996.A single-center study in a tertiary care research institution.A total of 56 women and 14 (...) men aged 18 to 55 years who met the 1988 Centers for Disease Control and Prevention case criteria for CFS and who withheld concomitant treatment with other medications.Oral hydrocortisone, 13 mg/m2 of body surface area every morning and 3 mg/m2 every afternoon, or placebo, for approximately 12 weeks.A global Wellness scale and other self-rating instruments were completed repeatedly before and during treatment. Resting and cosyntropin-stimulated cortisol levels were obtained before and at the end

1998 JAMA Controlled trial quality: predicted high

39. Hydrocortisone Valerate Ointment

Hydrocortisone Valerate Ointment Drug Approval Package: Hydrocortisone Valerate NDA# 75-043 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Hydrocortisone Valerate Ointment, USP Company: Taro Pharmaceuticals Inc. Application No.: 75-043 Approval Date: 8/25/1998 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 24, 2001 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing information in different file

1998 FDA - Drug Approval Package

40. Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. (Abstract)

Need for intravenous hydrocortisone in addition to oral prednisolone in patients admitted to hospital with severe asthma without ventilatory failure. 52 severely ill asthmatic patients requiring acute admission to hospital entered a double-blind placebo-controlled trial to determine whether intravenous hydrocortisone given in addition to high-dose oral prednisolone and standard bronchodilator therapy accelerated recovery. Patients who had been given parenteral steroids before admission (...) , by comparison with those who had not received such treatment, had been deteriorating for a shorter period before admission, had received more injected or nebulised bronchodilator therapy, and had higher admission peak flows. As judged by peak flow measurements 24 h after admission, parenteral steroids had no effect on the outcome, irrespective of whether they were given before or after (ie, intravenous hydrocortisone) admission. There is no evidence for the continued use of intravenous hydrocortisone

1986 Lancet Controlled trial quality: predicted high